A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2019-06, Vol.37 (S2), p.519-519
Hauptverfasser:	Lunning, M., Bierman, P., Bociek, R., Armitage, J., Heires, P., Blumel, S., Hohenstein, M., Lyden, L., Vose, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	B-cell lymphoma Inhibitor drugs Lymphocytes B Lymphoma Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	519
container_issue	S2
container_start_page	519
container_title	Hematological oncology
container_volume	37
creator	Lunning, M. Bierman, P. Bociek, R. Armitage, J. Heires, P. Blumel, S. Hohenstein, M. Lyden, L. Vose, J.
description
doi_str_mv	10.1002/hon.204_2631
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2242712275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2242712275</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1541-92339d53408e9fb0ae481a9e8ee3544ec975fbb254ba17b43a4398742c0b24053</originalsourceid><addsrcrecordid>eNp9kElOwzAUhi0EEmXYcQBLbEnxlCZeOq3TWHKTKgOoKysprgCVFhIqxI4jcABOx0lwKbBk9abv_e_pB-AMoz5GiFzerld9gpghA4r3QA8jzj2MBnwf9BAJQg8RSg7BUdfdI-RmKOyBDwGniSgkVErAoqxGMyivhK5EqdIxLBMJCxHLcgZFOoJlpmUuIqWVa2QxrCZRLrQqVPQ9VlFeuTVXqRROnYJMywJeqzKBudRiWsgRzHKXx7kYllk-gyMVx5U7rkU-ljD6fHsfSq2hnk2mSTYRJ-BgUS87e_oTj0Hlfhkmns7Gaii0N8c-wx4nlPIbnzIUWr5oUG1ZiGtuQ2upz5id88BfNA3xWVPjoGG0ZpSHASNz1BCGfHoMzne6j-36aWO7Z3O_3rQrd9IQwkiACQm21MWOmrfrrmvtwjy2dw91-2owMlv_jfPf_PrvcH-Hv9wt7eu_rEmy9G_vC6F-fFc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242712275</pqid></control><display><type>article</type><title>A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lunning, M. ; Bierman, P. ; Bociek, R. ; Armitage, J. ; Heires, P. ; Blumel, S. ; Hohenstein, M. ; Lyden, L. ; Vose, J.</creator><creatorcontrib>Lunning, M. ; Bierman, P. ; Bociek, R. ; Armitage, J. ; Heires, P. ; Blumel, S. ; Hohenstein, M. ; Lyden, L. ; Vose, J.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.204_2631</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>B-cell lymphoma ; Inhibitor drugs ; Lymphocytes B ; Lymphoma ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2019-06, Vol.37 (S2), p.519-519</ispartof><rights>2019 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1541-92339d53408e9fb0ae481a9e8ee3544ec975fbb254ba17b43a4398742c0b24053</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.204_2631$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.204_2631$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids></links><search><creatorcontrib>Lunning, M.</creatorcontrib><creatorcontrib>Bierman, P.</creatorcontrib><creatorcontrib>Bociek, R.</creatorcontrib><creatorcontrib>Armitage, J.</creatorcontrib><creatorcontrib>Heires, P.</creatorcontrib><creatorcontrib>Blumel, S.</creatorcontrib><creatorcontrib>Hohenstein, M.</creatorcontrib><creatorcontrib>Lyden, L.</creatorcontrib><creatorcontrib>Vose, J.</creatorcontrib><title>A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</title><title>Hematological oncology</title><subject>B-cell lymphoma</subject><subject>Inhibitor drugs</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kElOwzAUhi0EEmXYcQBLbEnxlCZeOq3TWHKTKgOoKysprgCVFhIqxI4jcABOx0lwKbBk9abv_e_pB-AMoz5GiFzerld9gpghA4r3QA8jzj2MBnwf9BAJQg8RSg7BUdfdI-RmKOyBDwGniSgkVErAoqxGMyivhK5EqdIxLBMJCxHLcgZFOoJlpmUuIqWVa2QxrCZRLrQqVPQ9VlFeuTVXqRROnYJMywJeqzKBudRiWsgRzHKXx7kYllk-gyMVx5U7rkU-ljD6fHsfSq2hnk2mSTYRJ-BgUS87e_oTj0Hlfhkmns7Gaii0N8c-wx4nlPIbnzIUWr5oUG1ZiGtuQ2upz5id88BfNA3xWVPjoGG0ZpSHASNz1BCGfHoMzne6j-36aWO7Z3O_3rQrd9IQwkiACQm21MWOmrfrrmvtwjy2dw91-2owMlv_jfPf_PrvcH-Hv9wt7eu_rEmy9G_vC6F-fFc</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Lunning, M.</creator><creator>Bierman, P.</creator><creator>Bociek, R.</creator><creator>Armitage, J.</creator><creator>Heires, P.</creator><creator>Blumel, S.</creator><creator>Hohenstein, M.</creator><creator>Lyden, L.</creator><creator>Vose, J.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201906</creationdate><title>A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</title><author>Lunning, M. ; Bierman, P. ; Bociek, R. ; Armitage, J. ; Heires, P. ; Blumel, S. ; Hohenstein, M. ; Lyden, L. ; Vose, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1541-92339d53408e9fb0ae481a9e8ee3544ec975fbb254ba17b43a4398742c0b24053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>B-cell lymphoma</topic><topic>Inhibitor drugs</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lunning, M.</creatorcontrib><creatorcontrib>Bierman, P.</creatorcontrib><creatorcontrib>Bociek, R.</creatorcontrib><creatorcontrib>Armitage, J.</creatorcontrib><creatorcontrib>Heires, P.</creatorcontrib><creatorcontrib>Blumel, S.</creatorcontrib><creatorcontrib>Hohenstein, M.</creatorcontrib><creatorcontrib>Lyden, L.</creatorcontrib><creatorcontrib>Vose, J.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lunning, M.</au><au>Bierman, P.</au><au>Bociek, R.</au><au>Armitage, J.</au><au>Heires, P.</au><au>Blumel, S.</au><au>Hohenstein, M.</au><au>Lyden, L.</au><au>Vose, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</atitle><jtitle>Hematological oncology</jtitle><date>2019-06</date><risdate>2019</risdate><volume>37</volume><issue>S2</issue><spage>519</spage><epage>519</epage><pages>519-519</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.204_2631</doi><tpages>2</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0278-0232
ispartof	Hematological oncology, 2019-06, Vol.37 (S2), p.519-519
issn	0278-0232 1099-1069
language	eng
recordid	cdi_proquest_journals_2242712275
source	Wiley Online Library Journals Frontfile Complete
subjects	B-cell lymphoma Inhibitor drugs Lymphocytes B Lymphoma Targeted cancer therapy
title	A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A30%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20PHASE%20IIA%20STUDY%20EVALUATING%20THE%20SAFETY%20AND%20TOLERABILITY%20OF%20UMBRALISIB%20AND%20IBRUTINIB%20IN%20PATIENTS%20WITH%20RELAPSED%20OR%20REFRACTORY%20DIFFUSE%20LARGE%20B%E2%80%90CELL%20LYMPHOMA&rft.jtitle=Hematological%20oncology&rft.au=Lunning,%20M.&rft.date=2019-06&rft.volume=37&rft.issue=S2&rft.spage=519&rft.epage=519&rft.pages=519-519&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.204_2631&rft_dat=%3Cproquest_cross%3E2242712275%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242712275&rft_id=info:pmid/&rfr_iscdi=true